Andrej Karpathy says that reinforcement learning is still terrible but better than all other AI learning approaches. Elon ...
Pfizer is backed by strong H1 results, a promising pipeline, improved financials, and solid valuation with long-term growth ...
The firm will use the funds to test its NaPi2b-targeted ADC in earlier lines of treatment and across tumor types, and another ADC in 5T4-expressing solid tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback